Aleva Neurotherapeutics Overview
Pro stress-test →Aleva Neurotherapeutics specializes in developing advanced Deep Brain Stimulation (DBS) technologies, particularly focusing on the Directional DBS system for treating neurological and psychiatric disorders, especially Parkinson's disease and essential tremor. Originating as a spin-off from the Swiss Federal Institute of Technology, the company partners with leading neurological clinics in Europe, with plans to expand into worldwide markets.
Strategic Profile
Pro stress-test →The company generates revenue through the sale of its directSTIM™ system, a DBS solution designed to eliminate surgical failures and non-responder patients, fully manufactured and assembled in Switzerland. Aleva has developed a proprietary neurostimulation platform based on microDBS technology with unique microfabricated devices enabling target-specific stimulation and optimization of current therapies.
Competitive Landscape
Pro stress-test →The Deep Brain Stimulation Devices landscape includes 20+ companies and 23+ pipeline devices. Aleva competes in the premium neuromodulation segment against larger medtech incumbents (Boston Scientific, Abbott, Medtronic) offering conventional DBS, and specialized players like HistoSonics (ultrasound neuromodulation). Aleva's directional, precision-targeted approach targets a differentiated segment but requires clinical evidence and payer adoption to scale.
Industry Context
Aleva Neurotherapeutics operates in Deep Brain Stimulation (DBS) Devices.
Key facts
Founded: 2008 · Headquarters: Lausanne, Switzerland · Employees: ~21 · Revenue: N/A · Market cap: N/A